Research has shown that MYC can enhance the sensitivity of tumor cells to glutamine synthetase inhibitors, and researchers believe that MYC can serve as a biomarker for glutamine synthetase inhibitor therapy, the judgement of MYC expression level will provide more treatment opportunities. Here, MYC is linked to neoplasm.